Legend Biotech Corp (LEGN) stock
LEGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$16.11+0.12 (+0.75%)
Close on Nov 17, 2026Market cap $2.98BP/E –Yield –
Legend Biotech gross margin
Gross margin is gross profit as a percentage of revenue.
Legend Biotech's gross margin for the twelve months ending Jun 30, 2026 was 57.2%. For fiscal 2025 it was 61.4%, against 65.5% the year before. The highest annual figure on record is 100.0% in fiscal 2020.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 61.4% | −4.1 |
| FY2024 | Dec 31, 2024 | 65.5% | +16.1 |
| FY2023 | Dec 31, 2023 | 49.4% | +5.3 |
| FY2022 | Dec 31, 2022 | 44.1% | −55.9 |
| FY2021 | Dec 31, 2021 | 100.0% | +0.0 |
| FY2020 | Dec 31, 2020 | 100.0% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 64.9% | +2.1 |
| Q1 FY2026 | Mar 31, 2026 | 42.5% | −21.8 |
| Q4 FY2025 | Dec 31, 2025 | 61.0% | −1.8 |
| Q3 FY2025 | Sep 30, 2025 | 58.4% | −8.8 |
| Q2 FY2025 | Jun 30, 2025 | 62.8% | −12.9 |
| Q1 FY2025 | Mar 31, 2025 | 64.4% | +16.6 |
| Q4 FY2024 | Dec 31, 2024 | 62.8% | +3.6 |
| Q3 FY2024 | Sep 30, 2024 | 67.2% | +12.5 |
| Q2 FY2024 | Jun 30, 2024 | 75.7% | +20.2 |
| Q1 FY2024 | Mar 31, 2024 | 47.8% | +45.8 |
| Q4 FY2023 | Dec 31, 2023 | 59.2% | +42.3 |
| Q3 FY2023 | Sep 30, 2023 | 54.7% | +47.8 |
| Q2 FY2023 | Jun 30, 2023 | 55.4% | – |
| Q1 FY2023 | Mar 31, 2023 | 2.0% | – |
| Q4 FY2022 | Dec 31, 2022 | 16.9% | – |
| Q3 FY2022 | Sep 30, 2022 | 6.9% | – |
See a number that looks wrong?